Generating AI analysis...
Revenue
$45.02B
-1.84% YoY
EPS (Basic)
$1.66
++22.96% YoY
Evidence Layer
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $45.02B | $45.86B | -1.84% |
Cost of Revenue | $10.79B | $11.94B | -9.60% |
Net Income | $9.42B | $7.62B | +23.59% |
EPS (Basic) | $1.66 | $1.35 | +22.96% |
EPS (Diluted) | $1.65 | $1.34 | +23.13% |
SG&A Expense | $9.63B | $10.46B | -7.88% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $208.73B | $219.48B | -4.90% |
Current Assets | $46.92B | $43.22B | +8.56% |
Total Liabilities | $115.64B | $126.92B | -8.89% |
Current Liabilities | $36.6B | $43.21B | -15.31% |
Stockholders' Equity | $92.8B | $92.29B | +0.56% |
Cash & Equivalents | $1.34B | $1.09B | +22.99% |
Long-Term Debt | $57.41B | $58B | -1.02% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $6.36B | $6.02B | +5.53% |
Investing Cash Flow | $4.79B | $4.28B | +12.16% |
Financing Cash Flow | $-10.9B | $-12.03B | +9.36% |
D&A | $4.91B | $5.22B | -6.07% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 20.9% | — | — |
ROE | 10.1% | — | — |
ROA | 4.5% | — | — |
Current Ratio | $1.282 | — | — |
Debt to Equity | $1.246 | — | — |
Other companies in Pharmaceuticals